表紙
市場調査レポート

Crestor(急性冠症候群)- 予測と市場分析

Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 312379
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
Crestor(急性冠症候群)- 予測と市場分析 Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
出版日: 2014年07月31日 ページ情報: 英文 60 Pages
概要

急性冠症候群(ACS)の現在の市場は、主として抗血栓剤、抗高血圧剤、スタチンで構成され、標準治療として十分に確立されているため、その多くはジェネリック医薬品です。ACS市場は、圧倒的多数の生活習慣病(肥満など)を伴う高齢化人口、代謝異常(糖尿病など)の有病率の増加によって、今後も成長が予測されています。

当レポートでは、ACSの治療薬であるCrestorについて調査分析し、疾患の概要と治療ガイドライン、競合情勢、製品情報、売上予測などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
    • 予後
    • QOL
  • 症状

第4章 疾患の管理

  • 治療の概要

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価

第6章 Crestor(rosuvastatin)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

目次

GlobalData has released its new PharmaPoint Drug Evaluation report, "Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Crestor remains the only branded statin in the 7MM covered in this forecast. It is the most potent of all of the HMG-CoA reductase inhibitors. Crestor faces steep competition from the generic statins, especially atorvastatin, which can boast a low cost and a preponderance of clinical trial data in support of its efficacy and safety. Nevertheless, when Crestor's patent expires in the US in 2016 and in the EU and Japan in 2017, the use of rosuvastatin is likely to increase, but the gain in sales is likely to be allocated to the new generic options.

Scope

  • Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Aricept for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for ACS
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Aricept performance
  • Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Crestor (rosuvastatin)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety

6.4. SWOT Analysis

  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Methodology for Forecasting Selected Portions of the Diagnosed Prevalent ACS Population
    • 7.4.2. Diagnosed Acute Coronary Syndrome Patients
    • 7.4.3. Percent Drug-Treated Patients
    • 7.4.4. General Pricing Assumptions
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Reviewer
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Antiplatelet Agents that Inhibit Platelet Activation
  • Table 2: Anticoagulants that Inhibit the Coagulatory Cascade
  • Table 3: Symptoms of Acute Coronary Syndrome
  • Table 4: Treatment Guidelines for Acute Coronary Syndromes (UA, NSTEMI, and STEMI)
  • Table 5: Most Prescribed Drugs for ACS by Class in the Global Markets, 2014
  • Table 6: Leading Treatments for Acute Coronary Syndrome, 2014
  • Table 7: Product Profile - Crestor (rosuvastatin)
  • Table 8: Crestor (rosuvastatin) SWOT Analysis, 2014
  • Table 9: Global Sales Forecasts ($m) for Crestor, 2013-2023
  • Table 10: Price Sources and Calculations, by Country
  • Table 11: Physicians Surveyed, By Country

List of Figures

  • Figure 1: The ACS Timeline and the Scope of GlobalData's ACS Report and Forecast
  • Figure 2: Progression of Coronary Artery Disease, Atherosclerotic Plaque Rupture, Thrombosis, and Acute Coronary Syndrome
  • Figure 3: Platelet and Coagulatory Factors Implicated in Thrombosis
  • Figure 4: Electrocardiography in the Diagnosis of ACS
Back to Top